Trial Profile
A Cancer Research UK Phase I/IIa clinical trial of BI-1206; an antibody to FcƔRIIB (CD32b), as a single agent and in combination with an anti-CD20 antibody in patients with CD32b positive B-cell malignancy.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs BI 1206 (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- 02 Oct 2020 Status changed from recruiting to completed.
- 26 Feb 2020 According to an BioInvent International media release, the company have agreed to limit the CRUK study to monotherapy, which is almost completed.
- 26 Feb 2020 According to an BioInvent International media release, given the overlap with company's own phase I/IIa trial of BI-1206 in combination with rituximab in Non-Hodgkin Lymphoma (NHL), and the fact that standard of care for patients with chronic lymphocytic leukemia (CLL) has dramatically evolved over the last few years, recruitment in the UK study has become increasingly challenging in particular since CRUK can only carry out trials in the UK.